BACKGROUND: The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasms (defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex. DESIGN AND METHODS: Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in 20 countries participating in EUROCARE-4 were analyzed. The period approach was used to estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5 years of follow up. RESULTS: The 5-year relative survival rate was 57% overall but varied markedly between the defined groups. Variation in survival within the groups was relatively limited across European regions and less than in previous years. Survival differences between men and women were small. The relative survival for patients with all lymphoid neoplasms decreased substantially after the age of 50. The proportion of 'not otherwise specified' diagnoses increased with advancing age. CONCLUSIONS: This is the first study to analyze survival of patients with lymphoid neoplasms, divided into groups characterized by similar epidemiological and clinical characteristics, providing a benchmark for more detailed analyses. This Europe-wide study suggests that previously noted differences in survival between regions have tended to decrease. The survival of patients with all neoplasms decreased markedly with age, while the proportion of 'not otherwise specified' diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care decreased with age, suggesting that older patients may not be receiving optimal treatment.
BACKGROUND: The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancerpatients (EUROCARE-4) database to produce a new grouping of hematologic neoplasms (defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex. DESIGN AND METHODS: Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in 20 countries participating in EUROCARE-4 were analyzed. The period approach was used to estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5 years of follow up. RESULTS: The 5-year relative survival rate was 57% overall but varied markedly between the defined groups. Variation in survival within the groups was relatively limited across European regions and less than in previous years. Survival differences between men and women were small. The relative survival for patients with all lymphoid neoplasms decreased substantially after the age of 50. The proportion of 'not otherwise specified' diagnoses increased with advancing age. CONCLUSIONS: This is the first study to analyze survival of patients with lymphoid neoplasms, divided into groups characterized by similar epidemiological and clinical characteristics, providing a benchmark for more detailed analyses. This Europe-wide study suggests that previously noted differences in survival between regions have tended to decrease. The survival of patients with all neoplasms decreased markedly with age, while the proportion of 'not otherwise specified' diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care decreased with age, suggesting that older patients may not be receiving optimal treatment.
Authors: N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield Journal: Histopathology Date: 2000-01 Impact factor: 5.087
Authors: Lindsay M Morton; Jennifer J Turner; James R Cerhan; Martha S Linet; Patrick A Treseler; Christina A Clarke; Andrew Jack; Wendy Cozen; Marc Maynadié; John J Spinelli; Adele Seniori Costantini; Thomas Rüdiger; Aldo Scarpa; Tongzhang Zheng; Dennis D Weisenburger Journal: Blood Date: 2007-03-27 Impact factor: 22.113
Authors: Graça M Dores; William F Anderson; Rochelle E Curtis; Ola Landgren; Evgenia Ostroumova; Elizabeth C Bluhm; Charles S Rabkin; Susan S Devesa; Martha S Linet Journal: Br J Haematol Date: 2007-10-17 Impact factor: 6.998
Authors: Christina A Clarke; Sally L Glaser; Ronald F Dorfman; Paige M Bracci; Erin Eberle; Elizabeth A Holly Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-01 Impact factor: 4.254
Authors: Klaus Podar; Yu-Tzu Tai; Teru Hideshima; Sonia Vallet; Paul G Richardson; Kenneth C Anderson Journal: Expert Opin Emerg Drugs Date: 2009-03 Impact factor: 4.191
Authors: Mariano Provencio; Pilar Sabín; José Gómez Codina; Antonio Rueda; Marta Llanos; Josep Gumá; Cristina Quero Blanco; Ana Blasco; Juan Ramón Delgado; Miguel Ángel Cruz; David Aguiar; Francisco Ramón García-Arroyo; Joaquín Herrero; Javier Lavernia; Natividad Martínez Banaclocha; Manuel Morales; José Fuster; Álvaro Sáez Cusi; Francisco Lobo; Delvys Rodríguez Abreu; Luis de la Cruz; Edelmira Antón; Alberto Rodríguez Jiménez; Alberto Arízcun; Xavi Pérez Journal: Clin Transl Oncol Date: 2012-05 Impact factor: 3.405
Authors: Djamila E Issa; Saskia A M van de Schans; Martine E D Chamuleau; Henrike E Karim-Kos; Marielle Wondergem; Peter C Huijgens; Jan Willem W Coebergh; Sonja Zweegman; Otto Visser Journal: Haematologica Date: 2014-12-15 Impact factor: 9.941
Authors: Andreas Engert; Carlo Balduini; Anneke Brand; Bertrand Coiffier; Catherine Cordonnier; Hartmut Döhner; Thom Duyvené de Wit; Sabine Eichinger; Willem Fibbe; Tony Green; Fleur de Haas; Achille Iolascon; Thierry Jaffredo; Francesco Rodeghiero; Gilles Salles; Jan Jacob Schuringa Journal: Haematologica Date: 2016-01-27 Impact factor: 9.941